Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lenvatinib + envafolimab
- Development stage
- Phase 2
- Lead developer
- 3D Medicines
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
Lenvatinib + envafolimab is a combination therapy under investigation for the treatment of various advanced cancers, including unresectable hepatocellular carcinoma (HCC) and endometrial cancer. Lenvatinib is an oral small molecule receptor tyrosine kinase inhibitor that targets multiple kinases involved in tumor angiogenesis and growth, such as VEGFR1–3, FGFR1–4, PDGFRα, KIT, and RET. Envafolimab is a monoclonal antibody immune checkpoint inhibitor targeting PD-L1; it is administered subcutaneously. The combination leverages antiangiogenic effects from lenvatinib with immune activation from envafolimab to enhance antitumor activity. Clinical studies have shown promising efficacy and manageable safety profiles for this regimen in patients with advanced HCC and endometrial cancer who have progressed after prior therapies[2][5][7].
- Other names
- lenvatinib mesylate
02
Targets
FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)KIT (c-KIT proto-oncogene receptor tyrosine kinase)CD274 (Programmed cell death protein 1 ligand 1)PDGFRA (Platelet-derived growth factor receptor alpha)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on lenvatinib + envafolimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lenvatinib + envafolimab.